Stem Cell Transplant With New Drug Combination for Acute Myeloid Leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of three chemotherapy drugs (clofarabine, busulfan, and melphalan) given before a stem cell transplant to treat acute myeloid leukemia (AML) in patients who have responded well to initial treatment. The goal is to improve how well the transplant works and how long patients survive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–60 years old
- Acute myeloid leukemia (excluding a subtype called APL) that has gone into remission (no visible cancer) after initial chemotherapy
- Either high-risk leukemia genes OR remaining leukemia cells detected by special testing
- Good overall health (able to do light activities; ECOG score 0–2)
- Have an available stem cell donor (sibling, unrelated, or half-matched relative) with compatible blood markers
- Normal or near-normal heart, lung, liver, and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
This trial tests whether a new drug combination (Dec-FB4) works better than an existing one (FB4) as preparation for a stem cell transplant in people with acute myeloid leukemia that is in remission. The goal is to improve outcomes for patients who have a suitable donor.
This trial tests a new conditioning regimen (MTBF) before a donor stem cell transplant for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. It aims to see if this approach can safely help prepare the body for the transplant and improve outcomes.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
This trial tests a new combination of two chemotherapy drugs, melphalan and cladribine, given before a stem cell transplant. It is designed for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.